Skip to content

Clinical Observation on Formula Granules of Huoxue-Jiangtang Decoction in Treating Prediabetes

Clinical Observation on Formula Granules of Huoxue-Jiangtang Decoction in Treating Prediabetes

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006100
Enrollment
Unknown
Registered
2022-06-12
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prediabetes States

Interventions

formula granules of Huoxue-Jiangtang Decoction+ lifestyle intervention group:formula granules of Huoxue-Jiangtang Decoction+ lifestyle intervention
Placebo + lifestyle intervention group:Placebo + lifestyle intervention
Huoxue-Jiangtang Decoction + lifestyle intervention group:Huoxue-Jiangtang Decoction + lifestyle intervention

Sponsors

Shenzhen Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnosis of "prediabetes", namely, the criteria of "impaired fasting glucose" and "abnormal glucose tolerance" in the classification of glucose metabolism state proposed by WHO in 1999. Which means that fasting glucose =6.1mmol/L, < 7.0mmol/L and/or OGTT 2-hour glucose =7.8mmol/L, < 11.1mmol/L. (2) According to the clinical Research Guidelines of Traditional Chinese Medicine New Drugs and Guidelines for the Diagnosis and Treatment of Prediabetes Combined with Disease and Syndrome(2021-03-02).The diagnosis of deficiency of qi and Yin syndrome in prediabetes is as following: main symptoms: tiredness and fatigue, dry throat and dry mouth; Second symptoms: easy to hunger, thirst, shortness of breath and unwillingness to speak, feverish sensation over the five centers, palpitation and insomnia, dark urine and constipation. Subjects should meet at least 1 criteria of primary symptoms plus 2 criteria of secondary symptoms. (3) =18 years old and < 70 years old. (4) HBA1c =6.5%. (5) Has not participated in any interventional clinical study or clinical trial in the past 3 months. (6) Be able and willing to sign written informed consent and complete the study.

Exclusion criteria

Exclusion criteria: (1) Patients with any type of diabetes whose diagnosis is clear. (2) Women during pregnancy and lactation. (3) Patients with chronic kidney disease (eGFR133µmol/L), severe liver dysfunction (any liver enzyme > 3 upper Limit Of Normal; abnormal coagulation function or bilirubin), severe cardiac dysfunction (such as NYHA ? or above heart failure, myocardial infarction, arrhythmia, etc), acute stage of cerebrovascular disease, or malignant diseases that are being treated or have not been fully alleviated or cured. (4) Patients who used high-dose probiotics (daily intake > 108cFU) in the last 6 months. (5) Patients who used glucocorticoids, cytokines that can stimulate the body's immune system, methotrexate and other immunosuppressants in the last 6 months. (6) Patients who systematacially used antibiotics in the last 3 months. (7) Patients who used local antibiotics in oral cavity within 7 days (such as toothpaste and mouthwash containing antibiotics, etc.). (8) Patients who ate erratically in the past 3 months (the same meal time interval of more than 2 hours). (9) Patients with untreated oral abscess. (10) Patients with oral fungal infection. (11) Patients with oral precancerous lesions or oral cancers. (12) Patients with chronic periodontal diseases requiring long-term treatment. (13) Patients who are allergic to any of the ingredients in linoleic solution. (14) Persons who are not suitable for participating in this project according to the researcher because of mental, psychological factors, etc.

Design outcomes

Primary

MeasureTime frame
2-hour postprandial blood glucose;Changes of syndrome score before and after treatment;fasting blood glucose;

Secondary

MeasureTime frame
Body Mass Index;2-hour postprandial insulin;dietary preference;Time of blood glucose reaching standard;Oral fat sensitivity;Procalcitonin;Adiponectin;IL-6;C-reactive protein;Weight;fasting insulin;

Countries

China

Contacts

Public ContactDeliang Liu
ldl2580@gzucm.edu.cn13924610289

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026